Remove FDA Approval Remove Generic Drugs Remove Medicine
article thumbnail

Pathbreakers: The journey of first generics

Pharmaceutical Technology

Since 2015, the US Food and Drug Administration (FDA) has approved more than 450 “first generics” or the first generic equivalent for a branded drug. These medicines comprise about 10% of all generics approved each year.

article thumbnail

Faster FDA Approvals Don’t Affect Generic Drug Availability or Cost

Pharmacy Checkers

I’m proud to share that PharmacyChecker has published a white paper that examines prices and availability of newly approved generic drugs. Out of 40 generic medications that were approved from 2017 to 2018, PharmacyChecker research found the following: 42.5% (17) are not available in the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

In the News: October Regulatory and Development Updates

Camargo

Approval of the Month: Companion Diagnostic for Bayer’s Vitrakvi Should Lead to Improved Patient Outcomes. In November 2017, Foundation Medicine received approval for FoundationOne CDx , a genomic profiling test for solid state tumors, which paved the way for partnerships with pharma companies’ therapeutics.

article thumbnail

After FDA approval, Alkermes plans soft launch for antipsychotic Lybalvi

pharmaphorum

The FDA approval of Alkermes’ new antipsychotic drug Lybalvi couldn’t have gone any better for the company, but it could still face a big challenge positioning the new drug in the highly genericised market. The post After FDA approval, Alkermes plans soft launch for antipsychotic Lybalvi appeared first on.

article thumbnail

Expanding ketamine’s horizons to treat rare neurological disorders

Pharmaceutical Technology

In 1970, the FDA approved ketamine as an anesthetic. The study of ketamine’s antidepressant effects has inspired research for different conditions, says Dr. Gerard Sanacora, director of the Depression Research Program at Yale School of Medicine, Connecticut. Moreover, securing funding is a significant challenge, says Schwenk.

Research 275
article thumbnail

Top 10 Pharma and Biotech M&As in the Past Decade

XTalks

This strategic move transformed Actavis into one of the largest pharma companies globally, with a strong presence across branded, generic and over-the-counter (OTC) medicines. The integration of Shire strengthened Takedas R&D pipeline, increasing its focus on innovative medicines and transformative therapies.

Marketing 104
article thumbnail

Humira biosimilars set the stage for long-awaited 2023 US launches

Pharmaceutical Technology

While small molecule drugs can be remade into identical generics, biologics are more complex. There are seven FDA-approved Humira biosimilars, of which Amgen’s Amjevita will be launched in January. Biosimilars have slightly different structures than the originator biologics but have the same effect in treating a disease.

Marketing 262